about
Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with RituximabDevelopment of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.Sensitive ligand-based protein quantification using immuno-PCR: A critical review of single-probe and proximity ligation assays.Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL.Post-induction residual disease in translocation t(12;21)-positive childhood ALL.Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research.Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.Interleukin-21 mRNA expression during virus infections.A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder.Erythropoietin receptor defect: a cause of primary polycythaemia.The Mycoplasma hominis P120 membrane protein contains a 216 amino acid hypervariable domain that is recognized by the human humoral immune response.Differential expression levels and methylation status of ROBO1 in mantle cell lymphoma and chronic lymphocytic leukaemia.Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia.A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.Nature and nurture: a case of transcending haematological pre-malignancies in a pair of monozygotic twins adding possible clues on the pathogenesis of B-cell proliferations.Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.Infectious complications after chemotherapy and stem cell transplantation in multiple myeloma: implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms.Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis.Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts.Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling.Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratoriesCharacterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in theCEBPAgene in patients with acute myeloid leukaemiaMultiplex PCR for the detection ofBCL-1/IGHandBCL-2/IGHgene rearrangements – clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphomaWilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications[Molecular biology diagnosis and monitoring in acute lymphoblastic leukemia and non-Hodgkin-lymphoma]Competitive PCR for quantification of minimal residual disease in acute lymphoblastic leukaemiaPrecise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome
P50
Q31150752-23C9E2A5-C0B2-4BF4-B0E7-D82374F7933BQ33873297-5CC99FA1-D538-4B5F-9BE2-8B4BEED98CEEQ38022075-8785E861-7E70-4813-9664-08590214B79BQ38029095-F4F5E7AB-248F-4EF4-A5C8-A55FE821CB3CQ38219536-9A5709D0-1345-469D-B6A7-C6F841FCDA55Q38322066-4D4C102C-A472-45DF-8B32-365ADE6F4747Q38360252-0F885245-4626-4F8D-87F3-EC8ADF89282CQ39015297-19EC21E3-7639-427D-A080-9B2B1C62DB95Q40762147-4E85A3EF-28F0-4F6D-AA8B-78AB14548E64Q43676402-9CC097D9-D817-44F5-9AC1-F9DED5FA7FA5Q44222759-570E2B11-2647-4368-B478-AB919D7DE7D9Q44443847-9162426D-BDC3-484C-9BAF-FB3CDD3E2633Q44703694-00A6C9D1-62D9-4B9B-8899-D9BF13EB8F10Q45420919-43801CFC-15EE-471D-B494-693202D5FC5EQ46099641-81A21AFA-044D-43B2-989C-BD242D14ED9FQ46768491-F1D0F516-186A-4168-8F8D-11AB94555425Q47608186-A58EDCDC-9DE1-40C7-A983-E72F367E560BQ48054544-397624CF-07A9-4C9B-A474-6E7F33F0BF7CQ48125811-D68021FD-197B-4915-8E29-204340AB53C6Q50858174-97BBFDBD-3F51-4C8E-9FDF-28782D8407D2Q51448188-DCADE3BE-CD5B-4BC9-9700-98CB1792DEDFQ51888520-88F2F5EC-4EE9-4C2F-8432-65EF38053902Q53590128-CE5B9385-385A-4843-81DB-F09E5686A210Q53610644-BA2EC63C-BBF8-4EAB-8F59-70A42587826DQ54204813-0729A56D-397E-4B8D-84F5-F05282250D54Q54534536-B6248C57-E054-40E9-91D8-F302D1E9FB53Q54546181-A6F3CAFB-3220-411F-898F-9E61E23F690AQ54605238-8CC04015-540F-43A3-891E-884321D420DAQ54631835-B8800CAC-D795-4185-911B-3BE1810832C7Q54634683-F6FE03C4-8A87-4EF4-8DCA-0A3D1F6A7E1AQ55057743-80FA404D-C06F-486D-920D-9EE07B93F139Q58023925-4B223F0A-C555-4C0F-96AE-8A216090E045Q59194228-DED38690-4AC9-4942-AD49-56B634033D08Q59194238-8395611B-8157-4ADD-9649-EDD3D197C156Q59194241-5E653433-131B-4B9B-9FA3-FCB02E15E477Q59194324-0B3A4541-CC83-4408-A8DB-EFCF587401AAQ59194331-2ADF781C-81EE-4960-BD3A-506F0333DABFQ71984356-C42A6595-71B0-451D-83D9-5F9215D80FBFQ73387740-85A0669F-5B40-40EA-A715-BC2EFA790A8EQ77601838-0ED72183-F4A8-49BF-A912-60384831A10D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Charlotte G Nyvold
@ast
Charlotte G Nyvold
@en
Charlotte G Nyvold
@es
Charlotte G Nyvold
@nl
type
label
Charlotte G Nyvold
@ast
Charlotte G Nyvold
@en
Charlotte G Nyvold
@es
Charlotte G Nyvold
@nl
prefLabel
Charlotte G Nyvold
@ast
Charlotte G Nyvold
@en
Charlotte G Nyvold
@es
Charlotte G Nyvold
@nl
P106
P21
P31
P496
0000-0002-0411-7594